SpringerLink
Log in

Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Major BCR-ABL1 mRNA in patients with chronic myeloid leukemia (CML) has generally been analysed by real-time polymerase chain reaction (PCR). Application of the international scale (IS) for the quantification of major BCR-ABL1 mRNA has been recommended in several sets of guidelines, including those of the European LeukemiaNet. The aim of this study was to clarify the efficacy of digital PCR technology for the IS of BCR-ABL1 mRNA in the patients with CML by comparing with real-time PCR.

Methods

The analysis of BCR-ABL1 mRNA was carried out by the Ipsogen® BCR-ABL1 Mbcr IS-MMR DX Kit (Qiagen), and the QuantStudio 3D Digital PCR System (Thermo Fisher Scientific‎) using 20 peripheral blood samples obtained from the 9 patients with CML at Sapporo Medical University Hospital.

Results

The correlation between the data obtained by digital PCR and by real-time PCR was really high at R = 0.96. The detection limit of digital PCR was up to 0.003% and was equal to IS with 0.01% or less in comparison with real-time PCR.

Conclusions

Digital PCR technology is promising for predicting the IS value with similar efficacy to real-time PCR and should be useful for simple monitoring of the effects of tyrosine kinase inhibitor (TKI) treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gabert J, Beillard E, van der Velden VH et al (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318–2357

    Article  CAS  PubMed  Google Scholar 

  2. Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. National Comprehensive Cancer Network (NCCN) (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Myelogenous Leukemia. Version 1. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 24 May 2017

  5. Usui N (2017) JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol 106:591–611

    Article  PubMed  Google Scholar 

  6. Cross NC, Hochhaus A, Müller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94:S219–S225

    Article  CAS  PubMed  Google Scholar 

  7. Hindson CM, Chevillet JR, Briggs HA et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Koizumi Y, Furuya D, Endo T et al (2018) Quantification of Wilms’ tumor 1 mRNA by digital polymerase chain reaction. Int J Hematol 107:230–234

    Article  CAS  PubMed  Google Scholar 

  9. Goh HG, Lin M, Fukushima T et al (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52:896–904

    Article  CAS  PubMed  Google Scholar 

  10. Jennings LJ, George D, Czech J et al (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16:174–179

    Article  CAS  PubMed  Google Scholar 

  11. Iacobucci I, Lonetti A, Venturi C et al (2014) Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 38:581–585

    Article  CAS  PubMed  Google Scholar 

  12. Alikian M, Whale AS, Akiki S et al (2017) RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem 63:525–531

    Article  CAS  PubMed  Google Scholar 

  13. Whelan JA, Russel NB, Whelan MA (2003) A method for the absolute quantification of cDNA using real time PCR. J Immunol Methods 278:261–269

    Article  CAS  PubMed  Google Scholar 

  14. Soverini S, De Benedittis C, Mancini M et al (2016) Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21:626–633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol 107:185–193

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan

    Daisuke Furuya, Mikako Moriai, Yuki Koizumi, Teruo Endo, Kouichi Asanuma, Nozomi Yanagihara & Satoshi Takahashi

  2. Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan

    Nozomi Yanagihara & Satoshi Takahashi

Authors
  1. Daisuke Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikako Moriai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruo Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouichi Asanuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nozomi Yanagihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Takahashi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Furuya, D., Moriai, M., Koizumi, Y. et al. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale. Int J Clin Oncol 24, 871–875 (2019). https://doi.org/10.1007/s10147-019-01419-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-019-01419-9

Keywords

Search

Navigation